Compositions and Methods for Treating Eyes and Methods of Preparation

Abstract

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

What is claimed is: 
     
         1 . A method for treating an ocular condition of an eye; wherein the method comprises a step of administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen. 
     
     
         2 . The method according to  claim 1 , wherein the ocular condition is one or more of: glaucoma, care after cataract surgery, care after LASIK surgery, care for a retina of the eye after cataract surgery, dry eyes disease, in preparation of an intraocular procedure, during the intraocular procedure, or promoting eyelash growth. 
     
     
         3 . The method according to  claim 1 , wherein the pharmaceutical composition comprises:
 (1) timolol maleate 0.5% and latanoprost 0.005%;   (2) timolol maleate 0.5%, brimonidine tartrate 0.2%, and dorzolamide 2% with a pH of 5.8 to 5.9;   (3) timolol maleate 0.5%, brimonidine tartrate 0.2%, dorzolamide 2%, and latanoprost 0.005% with a pH of 5.8 to 5.9;   (4) moxifloxacin HCl 0.5%;   (5) dexamethasone PO4 0.1% and moxifloxacin HCl 0.5% with a pH of 7 to 7.2;   (6) dexamethasone PO4 0.1%, moxifloxacin HCl 0.5%, and ketorolac tromethamine 0.5%;   (7) dexamethasone PO4 0.1%, moxifloxacin HCl 0.5%, and bromfenac 0.07%;   (8) prednisolone PO4 1% and gatifloxacin 0.5% with a pH of 6.5 to 7;   (9) prednisolone PO4 1% and ketorolac tromethamine 0.5% with a pH of 7.2 to 7.4;   (10) prednisolone PO4 1%, ketorolac tromethamine 0.5%, and gatifloxacin 0.5% with a pH of 8.5;   (11) prednisolone PO4 1% and bromfenac 0.07% with a pH of 8.3 to 8.5;   (12) prednisolone PO4 1%, gatifloxacin 0.5%, and bromfenac 0.07% with a pH of 8.3;   (13) amniotic cytokines extract comprising prostaglandin E2 (PGE2);   (14) phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%; or   (15) phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac 0.01%; and   wherein these percentages are with respect to weigh per volume.   
     
     
         4 . The method according to  claim 3 , wherein the amniotic cytokines extract further comprises growth factors and anti-inflammatory molecules of GDF11, WNT4, and thrombospondin-1. 
     
     
         5 . The method according to  claim 3 , wherein the prostaglandin E2 (PGE2) is at a concentration of at least 10,000 pg/mL. 
     
     
         6 . The method according to  claim 3 , wherein the pharmaceutical composition is preservative free. 
     
     
         7 . The method according to  claim 3 , wherein the pharmaceutical composition is preservative free, aside from boric acid. 
     
     
         8 . The method according to  claim 3 , wherein the pharmaceutical composition is preservative free, aside from benzalkonium chloride (BAK). 
     
     
         9 . The method according to  claim 1 , wherein the delivery device is selected from: an eye dropper or a syringe for intra-cameral injection. 
     
     
         10 . The method according to  claim 1 , wherein the predetermined dosing regimen is selected from: once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly. 
     
     
         11 . A method for treating an ocular condition of an eye; wherein the method comprises a step of administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen; wherein the pharmaceutical composition comprises at least two active pharmaceutical ingredients compounded and stored in communication with each other; wherein the method is more effective as compared against a preexisting method; wherein the preexisting method administers the at least two active pharmaceutical ingredients from at least two separate and different containers; wherein the method exposes the eye to less preservatives as compared against the current method. 
     
     
         12 . The method according to  claim 11 , wherein the ocular condition is one or more of: glaucoma, care after cataract surgery, care after LASIK surgery, care for a retina of the eye after cataract surgery, dry eyes disease, in preparation of an intraocular procedure, during the intraocular procedure, or promoting eyelash growth. 
     
     
         13 . The method according to  claim 11 , wherein the pharmaceutical composition comprises:
 (1) timolol maleate 0.5% and latanoprost 0.005%;   (2) timolol maleate 0.5%, brimonidine tartrate 0.2%, and dorzolamide 2% with a pH of 5.8 to 5.9;   (3) timolol maleate 0.5%, brimonidine tartrate 0.2%, dorzolamide 2%, and latanoprost 0.005% with a pH of 5.8 to 5.9;   (4) dexamethasone PO4 0.1% and moxifloxacin HCl 0.5% with a pH of 7 to 7.2;   (5) dexamethasone PO4 0.1%, moxifloxacin HCl 0.5%, and ketorolac tromethamine 0.5%;   (6) dexamethasone PO4 0.1%, moxifloxacin HCl 0.5%, and bromfenac 0.07%;   (7) prednisolone PO4 1% and gatifloxacin 0.5% with a pH of 6.5 to 7;   (8) prednisolone PO4 1% and ketorolac tromethamine 0.5% with a pH of 7.2 to 7.4;   (9) prednisolone PO4 1%, ketorolac tromethamine 0.5%, and gatifloxacin 0.5% with a pH of 8.5;   (10) prednisolone PO4 1% and bromfenac 0.07% with a pH of 8.3 to 8.5;   (11) prednisolone PO4 1%, gatifloxacin 0.5%, and bromfenac 0.07% with a pH of 8.3;   (12) amniotic cytokines extract comprising prostaglandin E2 (PGE2);   (13) phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%; or (14) phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac 0.01%; and   wherein these percentages are with respect to weigh per volume.   
     
     
         14 . The method according to  claim 13 , wherein the amniotic cytokines extract further comprises growth factors and anti-inflammatory molecules of GDF11, WNT4, and thrombospondin-1. 
     
     
         15 . The method according to  claim 13 , wherein the prostaglandin E2 (PGE2) is at a concentration of at least 10,000 pg/mL. 
     
     
         16 . The method according to  claim 13 , wherein the pharmaceutical composition is preservative free. 
     
     
         17 . The method according to  claim 13 , wherein the pharmaceutical composition is preservative free, aside from boric acid. 
     
     
         18 . The method according to  claim 13 , wherein the pharmaceutical composition is preservative free, aside from benzalkonium chloride (BAK). 
     
     
         19 . The method according to  claim 11 , wherein the delivery device is selected from: an eye dropper or a syringe for intra-cameral injection. 
     
     
         20 . The method according to  claim 11 , wherein the predetermined dosing regimen is selected from: once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly.